

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral.

MHRA-100543-PIP01-22-M03

Scope of the Application

Active Substance(s)

DOLUTEGRAVIR; LAMIVUDINE

Condition(s)

Treatment of Human Immunodeficiency virus type 1 (HIV-1) Infection

Pharmaceutical Form(s)

Film-coated tablet; Dispersible tablet

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

ViiV Healthcare UK Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, ViiV Healthcare UK Limited submitted to the licensing authority on 06/03/2024 12:12 GMT an application for a Modification

The procedure started on 06/06/2024 10:17 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100543-PIP01-22-M03

Of 30/07/2024 15:13 BST

On the adopted decision for DOLUTEGRAVIR; LAMIVUDINE (MHRA-100543-PIP01-22-M03) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan).

This decision applies to a Modification for DOLUTEGRAVIR; LAMIVUDINE, Film-coated tablet; Dispersible tablet , ORAL USE .

This decision is addressed to ViiV Healthcare UK Limited, 980 Great West Road, Middlesex, UNITED KINGDOM, TW8 9GS

ANNEX I

1. Waiver

1.1 Condition:

Treatment of Human Immunodeficiency virus type 1 (HIV-1) Infection The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 2 years of age. Pharmaceutical form(s): Film-coated tablet, Dispersible tablet Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of Human Immunodeficiency virus type 1 (HIV-1) Infection

2.2 Indication(s) targeted by the PIP:

• Lamivudine (3TC) / dolutegravir (DTG) fix-dose-combination (FDC) is to be indicated for use as a 2-drug complete regimen for the treatment of ART-naïve adolescents above 12 years to less than 18 years of age with plasma HIV-1 RNA less than 500,000 c/mL, or virologically suppressed adolescents, and without known viral drug resistance to either agent. • DTG/3TC FDC is to be indicated for use as a 2-drug complete regimen for the treatment of HIV-1 infection in paediatric subjects aged at least 2 years and older and weighing less than 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 2 years to less than 18 years of age.

2.4 Pharmaceutical Form(s):

Film-coated tablet Dispersible tablet

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Paediatric formulation development.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	2	Study 2 Single dose, crossover, relative bioavailability study of DTG plus 3TC paediatric formulation as compared to approved DTG and 3TC formulations. Study 3 Open-label, single-arm study to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of the fixed-dose combination of DTG/3TC in virologically suppressed HIV-1 infected paediatric subjects aged at least 2 years and weighing less than 40 kg of body weight.
Extrapolation, Modeling & Simulation Studies	3	Study 4 Extrapolation of efficacy from adult to adolescents 12 years to less than 18 years old weighing at least 40 kg. Study 5 Modelling and Simulation study to confirm dose and the extrapolation of use of the DTG/3TC FDC in antiretroviral-naïve children infected with HIV-1 from 2 years to less than 12 years

		of age and weighing between 10 kg to less than 40 kg. Study 6 Extrapolation of efficacy from adult to paediatric subjects aged at least 2 years and weighing less than 40 kg.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	31/12/2024
Deferral of one or more studies contained in the paediatric investigation plan:	Yes